ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/ERBB2-inhibitor-second-generation
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/ERBB2-inhibitor-second-generation
8
trial(s) found.
NCT07486817
Advanced
Phase 2
Not yet recruiting
Beamion 44: A Randomized, Open-label, Multi-center Phase IIa Platform Trial to Evaluate the Safety and Tolerability of Zongertinib Plus Platinum-based Doublet Chemotherapy With or Without Pembrolizumab (and Potential Other Combinations) in Treatment-naïve Patients With Locally Advanced/Metastatic Non-squamous NSCLC With Activating HER2 Mutations (
1479-0044
)
ERBB2 inhibitor,second generation
anti-PD-1 monoclonal antibody
Lung cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07195695
Curative
Phase 3
Recruiting
Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations (
1479-0032
)
ERBB2 inhibitor,second generation
Non-small cell lung cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT07185997
Advanced
Phase 3
Recruiting
A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA) (
FURMO-006
)
EGFR inhibitor,second generation
EGFR inhibitor,third generation
ERBB2 inhibitor,second generation
Non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT06897735
Advanced
Phase 1
Not yet recruiting
A Phase I Pilot Study to Evaluate the Bioequivalence, Pharmacokinetics, and Safety of Inhaled Afatinib Dimaleate Compared to the Reference Oral Afatinib Dimaleate in Healthy Smoking Volunteers (
EDDIS-a1
)
EGFR inhibitor,second generation
ERBB2 inhibitor,second generation
Cancer
Lung cancer
Melanoma
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06806982
Advanced
Phase 1
Recruiting
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of VRN101099 in Patients With HER2-Positive Solid Tumors (
VRN101099-01
)
ERBB2 inhibitor,second generation
HER2-positive solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
NCT06581432
Advanced
Phase 2
Recruiting
Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2-mutated or Overexpressed/Amplified Solid Tumours (
1479-0009
)
ERBB2 inhibitor,second generation
Cervical cancer
Gastroesophageal junction adenocarcinoma
NOT Breast cancer
NOT Colorectal adenocarcinoma
NOT Gastroesophageal cancer
NOT Pancreatic adenocarcinoma
NOT Pancreatic cancer
NOT Squamous non-small-cell lung cancer
Non-small cell lung cancer
Solid tumour
Urothelial carcinoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2109 - North Ryde - Macquarie University Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06151574
Advanced
Phase 3
Recruiting
Beamion LUNG 2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered Zongertinib (BI 1810631) Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Harbouring HER2 Tyrosine Kinase Domain Mutations (
1479-0008
)
ERBB2 inhibitor,second generation
Non-small cell lung cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
ACTRN12620000583943
Advanced
Phase 1 / Phase 2
Recruiting
An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and anti-tumour activity of once-daily oral treatment with EO1001 in patients with advanced cancer. (
EOHC-1001-01
)
EGFR inhibitor,second generation
ERBB2 inhibitor,second generation
Cancer
VIC
3004 - Melbourne, Southbank - Alfred Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3168 - Clayton - Monash Medical Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (6)
Not yet recruiting (2)
Recruitment Country and State
NSW (6)
VIC (5)
WA (4)
QLD (3)
SA (2)
NZ (1)
Phase
Phase 1 (2)
Phase 1 / Phase 2 (1)
Phase 2 (2)
Phase 3 (3)
Trial Type
Advanced (7)
Curative (1)
Cancer Therapy Class
ERBB2
100%
PD-1
38%
PD-1/PD-L1
38%
EGFR
38%
PD-L1
13%
Facility
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (3)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (3)
4102 - Woolloongabba - Princess Alexandra Hospital (3)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (3)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (2)
2065 - St Leonards - GenesisCare North Shore Private Hospital (2)
6150 - Murdoch - Fiona Stanley Hospital (1)
5042 - Bedford Park - Flinders Medical Centre (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
2109 - North Ryde - Macquarie University Hospital (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
2031 - Randwick - Prince of Wales Hospital (1)
3004 - Melbourne, Southbank - Alfred Health (1)
3168 - Clayton - Monash Medical Centre (1)
Cancer Type
Cancer
Solid tumour
Lung cancer
Respiratory tract cancer
Thoracic cancer
Non-small cell lung cancer
Melanoma
HER2-positive solid tumour
Cervical cancer
Gastric cancer
Gastric carcinoma
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
Gastrointestinal cancer
Gynaecological cancer
HPV-related cancer
HPV16-positive cancer
Oesophageal cancer
Upper gastrointestinal cancer
Urogenital cancer
Urothelial carcinoma
Viral-related cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy